This morning, the UK’s Food Standards Agency (FSA) announced some significant updates to its multi-year CBD Novel Foods approvals process,
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2 clinical trial for AJA001, a cannabinoid-based (FDA) botanical drug developed to treat behavioral symptoms associated with autism spectrum disorder (ASD).
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Food Standards Agency (FSA) have both issued regulatory updates on CBD this week.
Canada’s health regulator has announced plans to establish a regulatory framework enabling CBD products to be sold over the counter without a prescription.
In a long-awaited and major step forward for the UK’s CBD sector, the regulator has announced a new roadmap that could see the first products given official approval by Spring next year.
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
